Welcome to our dedicated page for ARCELLX SEC filings (Ticker: ACLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Arcellx, Inc. (NASDAQ: ACLX), a clinical-stage biotechnology company developing cell therapies and immunotherapies for cancer and other incurable diseases. Through these filings, investors can review how Arcellx reports its financial condition, collaboration revenue, research and development spending, and progress toward potential commercialization.
Arcellx uses periodic and current reports to disclose key information. For example, the company files Form 8-K to furnish press releases announcing quarterly financial results, as reflected in 8-K filings tied to results for quarters ended June 30 and September 30, 2025. These filings describe collaboration revenue associated with its partnership activities, research and development expenses related to clinical and preclinical programs, general and administrative expenses, and net losses as the company advances its pipeline.
In addition to 8-Ks, investors can use this page to find Arcellx’s annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These documents typically provide detailed discussions of the company’s lead BCMA-directed CAR T-cell therapy, anitocabtagene autoleucel (anito-cel), its Phase 2 iMMagine-1 and Phase 3 iMMagine-3 studies in relapsed or refractory multiple myeloma, regulatory designations, and its global strategic collaboration with Kite, a Gilead Company.
Stock Titan enhances these filings with AI-powered summaries that highlight key points such as revenue trends, R&D and G&A dynamics, cash runway disclosures, and material clinical or regulatory updates. Users can also review insider transaction reports on Form 4, proxy statements on Form DEF 14A, and other relevant submissions as they appear in the SEC’s EDGAR system. Together, these resources help investors and researchers quickly interpret Arcellx’s regulatory disclosures and understand the financial and operational context behind ACLX.
Arcellx, Inc. reported an insider stock transaction by its chief medical officer on a Form 4. On November 17, 2025, the officer sold 340 shares of common stock at $90 per share, leaving 284 shares beneficially owned directly after the sale. The filing notes that this sale was carried out under a pre-arranged Rule 10b5-1 trading plan that the reporting person entered into on March 23, 2025, which is designed to allow insiders to sell stock according to a preset schedule.
Arcellx, Inc. reported Q3 2025 results. Collaboration revenue was $4.9 million, down from $26.0 million a year ago as iMMagine-1 dosing and manufacturing wound down. The company posted a net loss of $55.8 million (basic and diluted $(0.99) per share) versus a $25.9 million loss last year.
Operating expenses rose to $66.7 million, with R&D $35.1 million (lower on reduced anito-cel trial activity) and G&A $31.6 million (higher commercial readiness and personnel costs). Other income was $6.0 million on interest.
Liquidity remained solid with $576.0 million in cash, cash equivalents and marketable securities at quarter-end, and management believes this funds operations into 2028. Contract liabilities to the Kite collaboration totaled $112.2 million. Year-to-date, Arcellx raised $131.6 million via its at-the-market program (1,905,715 shares). As of October 31, 2025, shares outstanding were 57,822,871. The company continues co-development of anito-cel with Kite, including the global Phase 3 iMMagine-3 in multiple myeloma.
Arcellx, Inc. furnished a current report on Form 8-K to announce that it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information under Item 2.02, including Exhibit 99.1, is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated. The report lists ACLX as the trading symbol on The Nasdaq Stock Market LLC and is signed by Chief Executive Officer Rami Elghandour on November 5, 2025.
Arcellx (ACLX) reported an insider transaction by its Chief Financial Officer. On 10/15/2025, the CFO sold 5,364 shares of common stock at a weighted average price of $91.0357, with trades ranging from $90.99 to $91.19, under a Rule 10b5-1 trading plan entered on March 21, 2025.
Following the sale, the officer beneficially owns 8,466 shares, held directly.
Arcellx (ACLX) reported insider activity by its Chief Financial Officer. On 10/03/2025, the CFO sold 4,882 shares of common stock at a weighted average price of $86.0036. On 10/06/2025, the CFO sold an additional 1,064 shares at a weighted average price of $86.2155. These sales were made under a Rule 10b5-1 trading plan entered on March 21, 2025. Following the transactions, the officer directly beneficially owned 13,830 shares.
ACLX: A Form 144 notice indicates a planned sale of up to 5,946 shares of common stock with an aggregate market value of $488,999.04. The shares are listed on NASDAQ and the sale is approximately dated October 3, 2025, with Morgan Stanley Smith Barney LLC named as broker.
The securities were acquired as Restricted Stock Units on January 3, 2025. The filing lists 55,458,912 shares outstanding as context.
Arcellx insider sales disclosed on Form 4: Christopher Heery, identified as a director and Chief Medical Officer, reported multiple sales of Arcellx common stock on 09/30/2025 executed under a Rule 10b5-1 trading plan established on March 23, 2025. The filings show three sale transactions totaling 21,034 shares — 5,300 shares at a weighted average price of $80.5518, 14,204 shares at a weighted average price of $81.4584, and 1,530 shares at a weighted average price of $82.198. Following those reported transactions the Form lists beneficial ownership amounts of 16,358, 2,154, and 624 shares on the respective lines. The Form 4 is signed and dated 09/30/2025.
Arcellx insider sale disclosed: Chief Medical Officer Christopher Heery reported a sale of 73 shares of Arcellx common stock on 09/29/2025 at $80.16 per share, leaving him with 21,658 shares held directly. The filing states the sale was executed under a Rule 10b5-1 trading plan established on March 23, 2025, indicating the transaction followed a prearranged compliance program.
This disclosure is a routine insider disposition that documents the number of shares sold, the price, and the resulting direct ownership stake; no derivative transactions or other material changes in ownership are reported.
Arcellx insider sale under 10b5-1 plan. The chief medical officer sold 12,396 shares of Arcellx common stock under a Rule 10b5-1 trading plan, at a weighted average price of $80.119 per share, and now beneficially owns 21,731 shares. The filing reports the transaction as a sale and identifies the sale price range as $80.00 to $80.41 with the weighted average disclosed. The reporting person indicates the sale was pre-arranged under a March 23, 2025 10b5-1 plan and offers to provide breakdown by price on request.
Heery Christopher, Chief Medical Officer of Arcellx, Inc. (ACLX), reported sales of company common stock under a Rule 10b5-1 trading plan. On 09/18/2025 he sold 3,343 shares at a weighted average price of $80.0085, leaving him with 34,427 shares beneficially owned after that transaction. On 09/19/2025 he sold an additional 300 shares at $80.00, leaving 34,127 shares beneficially owned. The Form 4 was signed by an attorney-in-fact on 09/19/2025.
The filing notes the sales were effected pursuant to a 10b5-1 plan entered March 23, 2025, and that the post-transaction totals include 284 shares acquired under the issuer's 2022 Employee Stock Purchase Plan on May 14, 2025. No derivative transactions or other changes were reported.
FAQ
What is the current stock price of ARCELLX (ACLX)?
What is the market cap of ARCELLX (ACLX)?
